Episodes of Keratitis during Treatment with Baricitinib for Alopecia Areata

On review of the literature regarding ocular side effects with JAK inhibitors, these seem rare but not exceptional. At this time, a casual link cannot be established. To exercise caution, clinicians should be aware of possible ocular adverse events in patients using JAK inhibitors and should also report these cases to the relevant drug safety agencies. Discontinuing the drug and switching to an alternative agent may also be necessary.